What are ANI Pharmaceuticals's profit margins?

ANI Pharmaceuticals (ANIP) runs a 60.8% gross margin and a 13.4% operating margin, with a 10.0% net margin.

Where do ANI Pharmaceuticals's ratios come from?

Every ratio is computed from ANI Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.

ANI Pharmaceuticals ANIP Ratios & Valuation

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	Q1 '26	Q4 '25	Q3 '25	Q2 '25	Q1 '25
Profitability
Gross margin	60.8%-0.5pp	61.4%+0.2pp	61.1%+0.1pp	61.1%+1.7pp	59.3%+0.1pp
Operating margin	13.4%+0.8pp	12.6%—	——	——	——
Net margin	10%+1.1pp	8.9%+4.0pp	4.9%+6.3pp	-1.4%+1.8pp	-3.1%-0.1pp
EBITDA margin	23.1%+0.2pp	22.9%+5.0pp	17.9%+6.6pp	11.3%+1.3pp	9.9%+1.3pp
Free cash flow margin	20.7%+1.3pp	19.4%+0.6pp	18.8%+2.0pp	16.8%+6.9pp	9.9%+2.1pp
Returns
Return on equity	18.8%+2.2pp	16.6%+7.7pp	8.9%+11.2pp	-2.3%+2.5pp	-4.8%-0.4pp
Return on assets	6.8%+1.0pp	5.7%+2.7pp	3%+3.9pp	-0.9%+1.0pp	-1.9%-0.2pp
Return on invested capital	17.2%+1.5pp	15.7%+7.7pp	7.9%+8.0pp	-0%+1.6pp	-1.6%+1.1pp
Efficiency
Asset turnover	0.7×0.0×	0.6×0.0×	0.6×0.0×	0.7×0.0×	0.6×0.0×
Inventory turnover	2.6×+0.1×	2.4×+0.3×	2.2×0.0×	2.2×0.0×	2.2×+0.2×
Liquidity
Current ratio	3.1×+0.4×	2.7×+0.1×	2.6×0.0×	2.5×-0.1×	2.7×-0.1×
Quick ratio	2.5×+0.3×	2.2×+0.2×	2×+0.1×	2×0.0×	2×0.0×
Cash ratio	1.3×+0.3×	1×+0.1×	1×+0.1×	0.9×+0.2×	0.7×0.0×
Leverage
Debt-to-equity	0.5×0.0×	0.6×0.0×	0.6×-0.1×	0.7×0.0×	0.8×0.0×
Debt-to-assets	0.2×0.0×	0.2×0.0×	0.2×0.0×	0.2×0.0×	0.2×0.0×
Net debt / EBITDA	-0×-0.2×	0.2×-0.2×	0.4×-0.8×	1.1×-1.3×	2.5×-0.9×
Per Share
Book value per share	$26.10+2.5%	$25.47+6.2%	$23.98+11.5%	$21.51+3.0%	$20.88-0.1%
Valuation
Market capitalization	$1.72B-2.8%	$1.77B-13.2%	$2.04B+40.8%	$1.45B-0.5%	$1.46B+25.4%
Enterprise value	$1.72B-5.0%	$1.81B-13.8%	$2.1B+35.6%	$1.55B-4.7%	$1.62B+21.0%
Price / earnings	18.7×-3.9×	22.6×-27.7×	50.3×—	——	——
Price / sales	1.9×-0.1×	2×-0.5×	2.5×+0.5×	1.9×-0.2×	2.2×+0.3×
Price / book	3.1×-0.2×	3.3×-0.8×	4×+0.7×	3.3×-0.2×	3.5×+0.6×
EV / EBITDA	8.1×-0.9×	8.9×-5.3×	14.2×-4.2×	18.3×-5.9×	24.2×-1.1×
EV / sales	1.9×-0.2×	2×-0.5×	2.5×+0.5×	2.1×-0.3×	2.4×+0.2×
Free cash flow yield	11.1%+1.4pp	9.7%+2.0pp	7.6%-1.0pp	8.7%+4.1pp	4.6%+0.5pp
Earnings yield	5.3%+0.9pp	4.4%+2.4pp	2%+2.7pp	-0.7%+0.7pp	-1.4%+0.1pp
Dividend yield	0%0.0pp	0.1%0.0pp	0.1%0.0pp	0.1%0.0pp	0.1%0.0pp

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are ANI Pharmaceuticals's profit margins?: ANI Pharmaceuticals (ANIP) runs a 60.8% gross margin and a 13.4% operating margin, with a 10.0% net margin.
Where do ANI Pharmaceuticals's ratios come from?: Every ratio is computed from ANI Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.